Kither Biotech
Carla Uslenghi has over 30 years of experience in the pharmaceutical industry. Carla is currently the Chief Medical Officer at Kither Biotech since March 2020. Prior to that, they worked at Amgen S.r.l. as a Sr Medical Advisor from March 2012 to February 2020. Carla also has experience as a Project Manager at Abbott Products S.p.A. from October 2007 to December 2011. Earlier in their career, they held the position of Medical Advisor at Solvay Pharma S.p.A. from February 1995 to September 2007 and Clinical Advisor at Poli Industria Chimica from January 1991 to February 1995.
Carla Uslenghi holds a Laurea in Scienze Biologiche degree from Università degli Studi di Torino. The duration of their studies and the field of study are not specified.
This person is not in any teams
Kither Biotech
Kither Biotech is a pharmaceutical product company that focuses its R&D activities on the development of new drugs. The R&D activities of the company mainly involve the development of new drugs to treat chronic inflammatory diseases.In recent years Kither has focused its first line of activities on the development of a small peptide(KIT2014) developed internally for the treatment of cystic fibrosis, a disease that predominantly affects the lungs and that currently has no cure. The KIT2014 peptide was assigned the Orphan Drug designation from the European Medicines Agency. The KIT2014 compound is currently undergoing the pre-clinical phase of clinical development.Kither’s product portfolio also includes a molecule (CL27), also developed internally, that is being developed for the treatment of Chronic Obstructive Pulmonary Diseases and Allergic Asthma. The company is about to start the pre-clinical phase of development of the CL27 molecule.